Zai Lab ZLAB
NASDAQ ZLAB
$26.31 -0.69 (-2.56%)
As of: Sep 4, 2026 · 2:37 PM EDT

Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026)

Zai Lab (ZLAB) posted Net Income towards Common Stockholders of -$51.0 million for Q1 2026, down 1.2% sequentially from -$50.4 million in Q4 2025, and down 5.32% YoY from -$53.9 million in Q1 2025.

Analysis

Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends

Zai Lab has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$51.0 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 5.32% year-over-year to -$51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$178.1 million (up 29.34% YoY) and the FY2025 annual result came in at -$175.5 million, up 31.73% from the prior year.
  • Net Income towards Common Stockholders retreated to -$51.0 million in Q1 2026 per ZLAB's latest filing, from -$50.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$36.0 million in Q3 2025 and troughed at -$161.2 million in Q3 2022.
  • A 5-year average of -$74.2 million and a median of -$61.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • The widest YoY moves for Net Income towards Common Stockholders: up 70.84% in 2022, down 67.19% in 2022.
  • Over 5 years, Net Income towards Common Stockholders stood at -$61.8 million in 2022, then plunged by 54.49% to -$95.4 million in 2023, then increased by 14.4% to -$81.7 million in 2024, then surged by 38.29% to -$50.4 million in 2025, then declined by 1.2% to -$51.0 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$51.0 million, -$50.4 million, and -$36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -644.37 Mn
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.40 Bn 27.56 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 Zai Lab 2.93 Bn 2.23 Bn 58.15 Mn -50.83 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -50.83 Mn
Mar 31, 2026 -51.02 Mn
Dec 31, 2025 -50.41 Mn
Sep 30, 2025 -35.96 Mn
Jun 30, 2025 -40.73 Mn
Mar 31, 2025 -48.44 Mn
Dec 31, 2024 -81.68 Mn
Sep 30, 2024 -41.67 Mn
Jun 30, 2024 -80.28 Mn
Mar 31, 2024 -53.47 Mn
Dec 31, 2023 -95.43 Mn
Sep 30, 2023 -69.15 Mn
Jun 30, 2023 -120.90 Mn
Mar 31, 2023 -49.14 Mn
Dec 31, 2022 -61.77 Mn
Sep 30, 2022 -161.19 Mn
Jun 30, 2022 -137.93 Mn
Mar 31, 2022 -82.39 Mn
Dec 31, 2021 -211.83 Mn
Sep 30, 2021 -96.41 Mn